# Rituximab in Patients With ST-elevation Myocardial Infarction

Study · id `cardio:ct-nct05211401` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05211401](<https://clinicaltrials.gov/study/NCT05211401>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05211401

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 372 participants.

## Technical summary

Registry record NCT05211401. Randomized; double masking; primary purpose treatment. Start 2022-06-01 (actual); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 372 participants (planned count; ClinicalTrials.gov record NCT05211401, source copy `cardio:ctgov-nct05211401-2026-11-10`, retrieved 2026-11-18)
- Started: 2022-06-01 (actual) (ClinicalTrials.gov record NCT05211401, source copy `cardio:ctgov-nct05211401-2026-11-10`, retrieved 2026-11-18)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT05211401, source copy `cardio:ctgov-nct05211401-2026-11-10`, retrieved 2026-11-18)
- Completion: 2028-05 (anticipated) (ClinicalTrials.gov record NCT05211401, source copy `cardio:ctgov-nct05211401-2026-11-10`, retrieved 2026-11-18)
- Countries: France (ClinicalTrials.gov record NCT05211401, source copy `cardio:ctgov-nct05211401-2026-11-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05211401-2026-11-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: Rituximab in Patients With ST-elevation Myocardial Infarction
- Acronym: RITA-MI2
- Condition: ST Elevated Myocardial Infarction
- Intervention (Drug): Active arm 1000 mg
- Intervention (Drug): Placebo arm
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Institut National de la Santé Et de la Recherche Médicale, France
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Institut National de la Santé Et de la Recherche Médicale, France (`cardio:org-institut-national-de-la-sante-et-de-la-recherche-medicale-3ba447`)

## Provenance

Content hash: 639e6f38367d6e6445b3e97b1c87adde143283635a614393c3b75cfadb751601
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
